Historical tap News Stories

TAP Downgrade: Weak Volumes Hit Molson Coors Now!!

Analysts cut Molson Coors (TAP) to Underperform after weak quarterly results and a cautious conference presentation. Key issues: volume declines, a $3.9B goodwill impairment, and a 400-role restructuring as the company pivots beyond beer.

TAP Stock: Aluminum Costs Hit; Buybacks Boost Now!

Molson Coors (TAP) reported a mixed quarter: modest EPS beat but revenue miss, while a sharp rise in aluminum costs and continued volume weakness threaten margins. Management announced $450M in cost cuts, a $4B buyback plan and confirmed the dividend — moves that could stabilize cash flow but hinge on execution.

Molson Coors (TAP) Hit by Aluminum Costs, Cuts EPS

Molson Coors (TAP) saw analyst downgrades and weakened guidance this week after Q4 results showed falling volumes and rising packaging costs. Management lowered 2026 EPS guidance to $4.61–$4.82 and flagged an approximately $125M headwind from aluminum, prompting Bank of America to cut its rating and price target.

TAP: Molson Coors Adds Dividend, Expands Buybacks!

Molson Coors (TAP) posted mixed Q4 results: an EPS beat but revenue miss, announced a $0.48/share dividend, expanded buyback capacity, and launched a $450M cost-savings plan. Commodity inflation and soft demand drove guidance concerns, prompting analyst cuts and a near-term stock pullback despite stronger cash flow and lower leverage.

Molson Coors (TAP) Surges Amid Short-Term Momentum

Molson Coors (TAP) showed a brief run of outperformance Feb. 10–12, rising over 6% cumulatively before a pullback on Feb. 13. The gains reflected relative strength versus peers and the S&P 500, with no new corporate announcements driving the move—momentum and sector flows were the likely catalysts.

Molson Coors (TAP) Pullback Before Feb 18 Call Q4!

Molson Coors (TAP) saw a short-lived rally in early February before easing into a modest pullback as investors await Q4 results and a CAGNY presentation on Feb 18. No material corporate headlines emerged last week; price action reflected momentum, analyst caution (downgrades and lower price targets) and longer-term consumption questions tied to GLP-1 drugs. Key catalysts remain the Feb 18 earnings release and subsequent investor presentation.